- Previous Close
0.6999 - Open
0.6509 - Bid 0.6250 x 4000
- Ask 0.6478 x 1000
- Day's Range
0.6143 - 0.6700 - 52 Week Range
0.4000 - 930.9600 - Volume
360,520 - Avg. Volume
3,363,131 - Market Cap (intraday)
710,848 - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
0.00 - EPS (TTM)
5,250.9600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
360.00
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
www.aeonbiopharma.comRecent News: AEON
View More
Performance Overview: AEON
Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AEON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AEON
View MoreValuation Measures
Market Cap
777.38k
Enterprise Value
13.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-348.25%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
42.01M
Diluted EPS (ttm)
5,250.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
13k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.3M
Research Analysis: AEON
View MoreCompany Insights: AEON
AEON does not have Company Insights